Literature DB >> 8772572

Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease.

M M Ritter1, A Frilling, P A Crossey, W Höppner, E R Maher, L Mulligan, B A Ponder, D Engelhardt.   

Abstract

Inherited pheochromocytomas are often part of familial syndromes, especially multiple endocrine neoplasia type 2 (MEN 2), retinal cerebellar hemangioblastomatosis [von Hippel-Lindau (vHL) disease] or neurofibromatosis type 1. It is not clear whether isolated familial pheochromocytoma exists as a separate clinical entity. In a family with pheochromocytomas in three generations and with at least seven affected members, we investigated by clinical and genetic analyses the presence or absence of associated conditions. The clinical investigations included ophthalmological and radiological studies for von Hippel-Lindau disease (magnetic resonance imaging of the brain, computed tomography of the abdomen, and direct ophthalmoscopy after mydriasis) and annual calcitonin stimulation tests for C cell disease in five members who agreed to regular follow-up. Besides the pheochromocytomas (so far, these have been multiple in five of seven individuals) no definite second associated condition was found. Genetic analysis did not identify any MEN 2-specific RET protooncogene point mutations (which are present in 97% of MEN 2a families). However, despite the complete absence of other clinical manifestations of the vHL disease (besides pheochromocytomas), a previously undescribed germline missense mutation in the vHL tumor suppressor gene was found (C775G transversion with a predicted substitution of a leucine by a valine at codon 259 in the putative vHL protein). We conclude that in this family the sole occurrence of pheochromocytoma is a variant of vHL disease.

Entities:  

Mesh:

Year:  1996        PMID: 8772572     DOI: 10.1210/jcem.81.3.8772572

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  The molecular basis of von Hippel-Lindau disease.

Authors:  O Iliopoulos; W G Kaelin
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

Review 2.  Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1.

Authors:  Giuseppe Opocher; Pierantonio Conton; Francesca Schiavi; Beatrice Macino; Franco Mantero
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.

Authors:  Yves Pastore; Katerina Jedlickova; Yongli Guan; Enli Liu; James Fahner; Henrik Hasle; Jaroslav F Prchal; Josef T Prchal
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

Review 4.  Hereditary paraganglioma targets diverse paraganglia.

Authors:  B E Baysal
Journal:  J Med Genet       Date:  2002-09       Impact factor: 6.318

Review 5.  Von Hippel-Lindau Disease.

Authors:  Jennifer J Findeis-Hosey; Kelly Q McMahon; Sarah K Findeis
Journal:  J Pediatr Genet       Date:  2016-04-04

6.  VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.

Authors:  Katja Knauth; Edward Cartwright; Stefan Freund; Mark Bycroft; Alexander Buchberger
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

7.  Mutation screening of VHL gene in a family with malignant bilateral pheochromocytoma: from isolated familial pheochromocytoma to von Hippel-Lindau disease.

Authors:  Shirin Hasani-Ranjbar; Mahsa M Amoli; Azadeh Ebrahim-Habibi; Vahid Haghpanah; Maryam Hejazi; Akbar Soltani; Bagher Larijani
Journal:  Fam Cancer       Date:  2009-08-01       Impact factor: 2.375

8.  R27X nonsense mutation of the SDHB gene in a patient with sporadic malignant paraganglioma.

Authors:  Masaki Naito; Takeshi Usui; Tamiko Tamanaha; Sachiko-Tsukamoto Kawashima; Hitomi Iogawa; Hanae Hagiwara; Takashi Kimura; Tetsuya Tagami; Manabu Kurosawa; Akira Shimatsu; Mitsuhide Naruse
Journal:  Endocrine       Date:  2009-05-05       Impact factor: 3.633

9.  Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease.

Authors:  Sena Hwang; Cheol Ryong Ku; Ji In Lee; Kyu Yeon Hur; Myung-Shik Lee; Chul-Ho Lee; Kyo Yeon Koo; Jin-Sung Lee; Yumie Rhee
Journal:  J Hum Genet       Date:  2014-07-31       Impact factor: 3.172

10.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.